Last reviewed · How we verify
Imlygic
Imlygic, developed by Johns Hopkins University, is a marketed oncolytic viral therapy for malignant melanoma. The drug's key strength lies in its unique mechanism of action, which directly targets and destroys cancer cells while stimulating an immune response. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Imlygic |
|---|---|
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant melanoma
Common side effects
- Fatigue
- Chills
- Pyrexia
- Nausea
- Influenza-like illness
- Injection site pain
- Rash
- Dermatitis
Serious adverse events
- Cellulitis
- Disseminated herpetic infections
- Pneumonitis
- Glomerulonephritis
- Vasculitis
- Deep vein thrombosis
- Obstructive airway disorder
- Herpetic keratitis
- Plasmacytoma at injection site
- Worsening psoriasis
Key clinical trials
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (PHASE2)
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (PHASE2)
- Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (PHASE1, PHASE2)
- Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 (PHASE1)
- Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
- TVEC and Preop Radiation for Sarcoma (8 ml Dose) (PHASE1, PHASE2)
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (PHASE1)
- Neoadjuvant Intralesional Injection of Talimogene Laherparepvec (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imlygic CI brief — competitive landscape report
- Imlygic updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI